Ruth Plummer

Summary

Affiliation: University of Newcastle
Country: UK

Publications

  1. ncbi request reprint Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers
    Ruth Plummer
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
    Clin Cancer Res 13:6187-94. 2007
  2. pmc A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
    Ruth Plummer
    Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Newcastle upon Tyne, UK
    Cancer Chemother Pharmacol 71:93-101. 2013
  3. doi request reprint A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
    Ruth Plummer
    Institute for Cancer Research, Paul O Gorman Building, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK
    Cancer Chemother Pharmacol 71:1191-9. 2013
  4. ncbi request reprint A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies
    Ruth Plummer
    Northern Centre for Cancer Treatment, Newcastle upon Tyne, United Kingdom
    Clin Cancer Res 14:8288-94. 2008
  5. pmc Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
    Ruth Plummer
    Northern Institute for Cancer Research, Newcastle University, Paul O Gorman Building, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK
    Breast Cancer Res 13:218. 2011
  6. doi request reprint PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications
    Yvette Drew
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
    Drug Resist Updat 12:153-6. 2009
  7. doi request reprint The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer
    Yvette Drew
    Northern Institute for Cancer Research, Paul O Gorman Building, Newcastle University, Framlington Place, Newcastle upon Tyne, UK
    Curr Opin Obstet Gynecol 22:67-71. 2010
  8. doi request reprint Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target
    Ruth Plummer
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
    Clin Cancer Res 16:4527-31. 2010
  9. pmc Targeting the DNA double strand break repair machinery in prostate cancer
    Fadhel S Shaheen
    The Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom
    PLoS ONE 6:e20311. 2011
  10. pmc Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors
    Ruth Plummer
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
    Clin Cancer Res 14:7917-23. 2008

Detail Information

Publications11

  1. ncbi request reprint Phase 1 and pharmacokinetic study of lexatumumab in patients with advanced cancers
    Ruth Plummer
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
    Clin Cancer Res 13:6187-94. 2007
    ....
  2. pmc A Phase I study of pazopanib in combination with gemcitabine in patients with advanced solid tumors
    Ruth Plummer
    Sir Bobby Robson Cancer Trials Research Centre, Northern Centre for Cancer Care, Newcastle upon Tyne, UK
    Cancer Chemother Pharmacol 71:93-101. 2013
    ..Pazopanib plus gemcitabine combination therapy was explored in patients with advanced solid tumors...
  3. doi request reprint A phase II study of the potent PARP inhibitor, Rucaparib (PF-01367338, AG014699), with temozolomide in patients with metastatic melanoma demonstrating evidence of chemopotentiation
    Ruth Plummer
    Institute for Cancer Research, Paul O Gorman Building, Newcastle University, Framlington Place, Newcastle upon Tyne NE2 4HH, UK
    Cancer Chemother Pharmacol 71:1191-9. 2013
    ..We report the results of a phase II study of intravenous rucaparib 12 mg/m(2) and oral temozolomide 200 mg/m(2) on days 1-5 every 28 days in patients with advanced metastatic melanoma...
  4. ncbi request reprint A phase I and pharmacokinetic study of ixabepilone in combination with Carboplatin in patients with advanced solid malignancies
    Ruth Plummer
    Northern Centre for Cancer Treatment, Newcastle upon Tyne, United Kingdom
    Clin Cancer Res 14:8288-94. 2008
    ..To determine the recommended phase II dose of combination ixabepilone plus carboplatin based on the maximum tolerated dose, pharmacokinetics, optimum schedule, and safety...
  5. pmc Poly(ADP-ribose) polymerase inhibition: a new direction for BRCA and triple-negative breast cancer?
    Ruth Plummer
    Northern Institute for Cancer Research, Newcastle University, Paul O Gorman Building, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK
    Breast Cancer Res 13:218. 2011
    ..Overall, PARP inhibitors represent a potentially important new class of anti-cancer agents with two potential modes of action, as single agents causing synthetic lethality and as chemo-potentiating agents...
  6. doi request reprint PARP inhibitors in cancer therapy: two modes of attack on the cancer cell widening the clinical applications
    Yvette Drew
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
    Drug Resist Updat 12:153-6. 2009
    ..The current clinical data are discussed within this review with reference to the preclinical models which predicted activity and also future directions and the possible dangers/pitfalls of this clinical strategy are explored...
  7. doi request reprint The emerging potential of poly(ADP-ribose) polymerase inhibitors in the treatment of breast cancer
    Yvette Drew
    Northern Institute for Cancer Research, Paul O Gorman Building, Newcastle University, Framlington Place, Newcastle upon Tyne, UK
    Curr Opin Obstet Gynecol 22:67-71. 2010
    ..Why PARP inhibitors are synthetically lethal to certain tumours and the specific role this class of drugs may play in the treatment of breast cancer is reviewed...
  8. doi request reprint Perspective on the pipeline of drugs being developed with modulation of DNA damage as a target
    Ruth Plummer
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
    Clin Cancer Res 16:4527-31. 2010
    ..An increased understanding of the biology and interaction of the DNA repair pathways also means that rational combination of DNA repair inhibitors may also give great benefit in the clinic...
  9. pmc Targeting the DNA double strand break repair machinery in prostate cancer
    Fadhel S Shaheen
    The Northern Institute for Cancer Research, Medical School, Newcastle University, Newcastle upon Tyne, United Kingdom
    PLoS ONE 6:e20311. 2011
    ..Additionally, the augmented effect resulting from combining both inhibitors may have a significant implication for the treatment of CaP patients who have a defect in one of the two DSB repair pathways...
  10. pmc Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors
    Ruth Plummer
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, United Kingdom
    Clin Cancer Res 14:7917-23. 2008
    ..The article reports safety, efficacy, pharmacokinetic, and pharmacodynamic results of the first-in-class trial of a PARP inhibitor, AG014699, combined with temozolomide in adults with advanced malignancy...
  11. doi request reprint Phase I study of MG98, an oligonucleotide antisense inhibitor of human DNA methyltransferase 1, given as a 7-day infusion in patients with advanced solid tumors
    Ruth Plummer
    Northern Institute for Cancer Research, Newcastle University, Newcastle upon Tyne, UK
    Clin Cancer Res 15:3177-83. 2009
    ....